Prothena Corporation plc Ordinary Shares, also called Prothena, is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. Read More The company was founded in December 1969 and is headquartered in Dublin, Ireland.